Search Results - "Fröhling, S"
-
1
Optimizing panel-based tumor mutational burden (TMB) measurement
Published in Annals of oncology (01-09-2019)“…Panel sequencing based estimates of tumor mutational burden (psTMB) are increasingly replacing whole exome sequencing (WES) tumor mutational burden as…”
Get full text
Journal Article -
2
Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia
Published in Leukemia (01-06-2015)“…Genetic abnormalities are a hallmark of cancer. Hereby, cytogenetic aberrations and small-scale abnormalities, such as single-nucleotide variations and…”
Get full text
Journal Article -
3
Biology-guided precision medicine in rare cancers: Lessons from sarcomas and neuroendocrine tumours
Published in Seminars in cancer biology (01-09-2022)“…Rare cancers, which collectively account for almost 25 % of all malignancies, are poorly understood in terms of their aetiology and pathogenesis and are…”
Get full text
Journal Article -
4
Real‐world data for precision cancer medicine—A European perspective
Published in Genes chromosomes & cancer (01-09-2023)“…Leveraging real‐world data (RWD) for drug access is necessary to overcome a key challenge of modern precision oncology: tackling numerous low‐prevalence…”
Get full text
Journal Article -
5
RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia
Published in Leukemia (01-10-2018)“…Many cases of AML are associated with mutational activation of receptor tyrosine kinases (RTKs) such as FLT3. However, RTK inhibitors have limited clinical…”
Get full text
Journal Article -
6
Neoadjuvant irradiation of retroperitoneal soft tissue sarcoma with ions (Retro-Ion): study protocol for a randomized phase II pilot trial
Published in Current controlled trials in cardiovascular medicine (12-02-2021)“…Following surgery for soft tissue sarcoma of the retroperitoneum, the predominant pattern of failure is local recurrence, which remains the main cause of…”
Get full text
Journal Article -
7
Radiotherapy in the treatment of aggressive fibromatosis: experience from a single institution
Published in Radiation oncology (London, England) (05-06-2020)“…Desmoid-type fibromatosis is a rare, potentially locally aggressive disease. Herein we present our experience in the treatment with radiotherapy. In total 40…”
Get full text
Journal Article -
8
High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma
Published in British journal of dermatology (1951) (01-12-2021)“…Summary Background Eccrine porocarcinoma (EPC) is a rare skin cancer arising from the eccrine sweat glands. Due to the lack of effective therapies, metastasis…”
Get full text
Journal Article -
9
Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen‐activated protein kinase pathway
Published in British journal of dermatology (1951) (01-03-2022)“…Summary Background Epithelioid haemangioma (EH) arising from the skin is a benign vascular tumour with marked inflammatory cell infiltration, which exhibits a…”
Get full text
Journal Article -
10
Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)
Published in NPJ precision oncology (09-06-2022)“…Homologous repair deficiency (HRD) is present in many cancer types at variable prevalence and can indicate response to platinum-based chemotherapy and PARP…”
Get full text
Journal Article -
11
Phase iii study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia
Published in Leukemia (01-11-2004)“…The purpose of our study was (i) to evaluate the impact of all-trans retinoic acid (ATRA) given as adjunct to chemotherapy and (ii) to compare second…”
Get full text
Journal Article -
12
Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance
Published in Leukemia (01-02-2013)“…Recently, the p53-miR-34a network has been identified to have an important role in tumorigenesis. As in acute myeloid leukemia with complex karyotype (CK-AML)…”
Get full text
Journal Article -
13
Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma
Published in Annals of oncology (01-01-2017)“…Sinonasal carcinomas (SNCs) comprise various rare tumor types that are characterized by marked histologic diversity and largely unknown molecular profiles, yet…”
Get full text
Journal Article -
14
Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms
Published in Annals of oncology (01-10-2018)Get full text
Journal Article -
15
71: Targeted cancer genetics
Published in European journal of cancer (1990) (01-07-2014)Get full text
Journal Article -
16
Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial
Published in Leukemia (01-08-2003)“…The objective of the AML HD93 treatment trial was to evaluate the outcome in young adults with acute myeloid leukemia (AML) after postremission therapy was…”
Get full text
Journal Article -
17
TRANSCRIPTIONAL AND GENOMIC INTRA‐TUMOR HETEROGENEITY DRIVES SUBCLONE SPECIFIC DRUG RESPONSES IN DIFFUSE LARGE B CELL LYMPHOMA
Published in Hematological oncology (01-06-2019)Get full text
Journal Article -
18
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial
Published in ESMO open (01-12-2021)“…Approvals of cancer therapeutics are primarily disease entity specific. Current molecular diagnostic approaches frequently identify actionable alterations in…”
Get full text
Journal Article -
19
JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia
Published in Leukemia (01-05-2017)“…The transcription factor JUN is frequently overexpressed in multiple genetic subtypes of acute myeloid leukemia (AML); however, the functional role of JUN in…”
Get full text
Journal Article -
20
PO-451 Targeted proteomics to improve therapy stratification of cancer patients
Published in ESMO open (01-07-2018)“…IntroductionThe heterogeneity of tumours calls for patient stratification to select the most effective, personalised therapies. The NCT MASTER (Molecularly…”
Get full text
Journal Article